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Abstract 
The presence of a monoclonal protein in the serum 
and/or urine is a common clinical condition that 
increases in incidence with age. Although the 
diagnosis is most often monoclonal gammopathy of 
undetermined significance (MGUS) there are many 
conditions associated with the presence of a 
monoclonal protein in a patient. Several of these are 
potentially life-threatening and the presence of the 
M protein should serve as a clue to these diagnosis. 
The size of the monoclonal protein has very little 
bearing on the association with other disorders. This 
concise review highlights the better known 
associations between monoclonal proteins and other 
symptoms, making them monoclonal gammopathy 
of clinical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 The concept of monoclonal gammopathy of 
undetermined significance (MGUS) was coined by 
Dr Robert A. Kyle in 1978 to describe a clinical 
state when a monoclonal protein is identified in a 
patient’s serum or urine in the absence of evidence 
of end organ damage such as multiple myeloma, 
primary (AL) amyloidosis or Waldenstrom’s 
macroglobulinemia.1 The presence of a monoclonal 
protein by necessity infers the existence of clonal 
plasma cells in the bone marrow that produce the 
protein and for this reason, MGUS belongs to the 
spectrum of clonal plasma cell disorders. This 
group of conditions varies from the benign MGUS 
to the highly malignant primary plasma cell 
leukemia. The current diagnostic criteria for MGUS 
require that there are less than 10% clonal plasma 
cells in the bone marrow and the monoclonal 
protein concentration in the serum must be less than 
30g/L (for IgG, IgA, and IgM).2 In the case of 
immunoglobulin light chain MGUS, the involved 
immunoglobulin light chain (kappa or lambda) must 
be elevated and the monoclonal protein in the urine 
must be less than 500mg/24 hours.2-4  
 MGUS is common and found in 3.2% of the 
general population, with a prevalence that increases 
with age: 0.3% of the population younger than 50 
years will have this protein, while up to 8% of the 
population above the age of 80 will have a 
detectable monoclonal protein.5-6 There are 
considerable ethnic differences in the prevalence of 
the condition and it is more common and appears at 
a younger age in African Americans.3,6-7 The main 
clinical significance of MGUS has been due to its 
risk of progression to multiple myeloma, 
amyloidosis or Waldenstrom’s macroglobulinemia. 
It has been argued that MGUS is a necessary 
prerequisite for the development of multiple 
myeloma since retrospective analysis of serum 
samples from patients who subsequently developed 
multiple myeloma were found to have the signature 
monoclonal protein present sometimes for years in 
advance.8-9 However, this observation is not 
unexpected since kinetic studies from the 1960s 
showed that for a clonal plasma cell to grow and 
reach a clinically significant size, more than a 
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decade has to pass.10 This seminal observation has 
been confirmed with more recent analysis.11 
Various models have been developed to try and 
determine the risk of progression to multiple 
myeloma at the time of diagnosis and provide some 
guidance on the frequency of follow up in this 
condition. Part of the problem with this approach 
relates to rigid cut-offs that have been imposed on 
the diagnostic categories (MGUS, smoldering 
multiple myeloma and multiple myeloma). The 
result is that there are patients who do not meet 
these rigid criteria and in such situations (as always) 
the clinical judgment of the physician becomes 
essential rather than following guidelines blindly.  
 In clinical practice, the diagnosis of MGUS 
may appear to be easy – the presence of the 
monoclonal protein without the ‘CRAB’ features 
that define multiple myeloma (hyperCalcemia, 
Renal failure, Anemia and Bone lesions). Moreover, 
there is the impression that when the size of the 
monoclonal protein is small (especially when much 
smaller than 30g/L), then the risk of multiple 
myeloma is trivial or non-existent and the label of 
MGUS quickly applied. This can expose the patient 
to potential harm for several reasons: (i) Such 
thinking will inevitably exclude patients with light 
chain multiple myeloma (maybe up to 10% of 
patients), (ii) eliminate from consideration patients 
with oligosecretory or non-secretory multiple 
myeloma (~3%), (iii) exclude the possibility of AL 
amyloidosis, and (iv) likely exclude from 
consideration important clinical conditions 
associated with MGUS. The list of ‘benign’ 
conditions associated with MGUS keeps 
increasing.12 Therefore MGUS should only be 
diagnosed if the physician consciously excludes 
these conditions with a comprehensive history and 
physical examination and targeted testing as 
clinically indicated. The purpose of this review is to 
highlight the better known associations between 
MGUS and other conditions and discuss the 
relevant clinical features of these syndromes so as 
to increase awareness of these associations and 
facilitate diagnosis and therapy. Some of these 
associations lead to well defined clinical syndromes 
affecting several organ systems while other 
manifestations are restricted to single organs. It is 
important to emphasize that in general there is no 
linear association between the size of the 
monoclonal protein and the presence of associated 
diseases or syndromes and therefore, it is the 
presence of the monoclonal protein that should be 
considered as an aid to the diagnosis or exclusion of 
these specific conditions. 
 
Multisystem  
AL or AH amyloidosis 
Almost 90% of all patients with amyloidosis 
will have a syndrome related to the deposition of 
immunoglobulin light (AL) or heavy chains (AH) 
or both (AL/AH).13 The deposited protein appears 
as an amorphous material on hematoxylin and eosin 
(H&E) staining and demonstrates apple-green 
birefringence with Congo red staining under plane 
polarized light. Diagnosis of amyloidosis depends 
on recognition of the various clinical syndromes 
that patients can present with. The major organs 
affected (alone or in combination) are the heart 
(restrictive cardiomyopathy), the kidneys (nephrotic 
syndrome), peripheral neuropathy, gastrointestinal 
involvement (upper gut: macroglossia, dysphagia, 
early satiety, unexplained nausea and vomiting; 
lower gut: constipation or diarrhea alternating with 
constipation), weight loss, carpal tunnel syndrome, 
liver involvement (non-tender hepatomegaly; 
elevated alkaline phosphatase), autonomic 
dysfunction, purpura (typically periorbital), and 
vascular disease (lower extremity or jaw 
claudication).14-15 In patients with symptoms of 
heart failure without hypertension or diabetes 
mellitus, amyloid cardiomyopathy is an important 
consideration, especially if there is left ventricular 
hypertrophy or a pseudo-infarction pattern on the 
electrocardiogram.15 The same approach applies to 
patients with unexplained nephrotic range 
proteinuria. The urine protein electrophoretic 
pattern can provide an important clue: if the protein 
is mainly albumin, AL amyloidosis needs to be 
excluded. If however, the protein is mainly due to 
the monoclonal immunoglobulin or light chains 
(‘Bence Jones proteinuria’) then multiple myeloma 
is much more likely. Although it is more common 
to have lambda light chains as a cause of 
amyloidosis, this cannot be used to exclude this 
disease. Indeed, perhaps 30% of patients with AL 
amyloidosis may have immunoglobulin kappa light 
chains. Diagnosis of amyloidosis depends on a 
tissue biopsy and it can never be excluded simply 
because the serum protein electrophoresis and 
immunofixation are negative. Nor is it excluded if 
the serum immunoglobulin free light chains are 
normal since patients can have non AL amyloidosis 
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or (rarely) even AL amyloidosis. The most 
accessible organs for biopsy include the bone 
marrow and subcutaneous fat – together they can 
identify amyloidosis in up to 90% of patients.13 If 
these are negative, then a biopsy of the major 
affected organ (e.g. kidney or heart) will yield the 
diagnosis. It is critical to identify the amyloidogenic 
protein properly to ensure appropriate therapy. 
Specifically, the presence of a monoclonal protein 
in the serum or urine does not guarantee that the 
amyloidosis is due to the plasma cell disorder and 
typing is the only definitive way to determine the 
identity of the causative protein.16 This is ideally 
done by laser capture micro-dissection followed by 
MALDI-TOFF mass spectrometry.17 Therapy of AL 
amyloidosis is complex and depends on the organs 
affected, their severity as well as the performance 
status of the patient.13,15,18 Although in many 
patients with AL amyloidosis the clonal plasma cell 
burden in the bone marrow is less than 10%, others 
may have higher fractions of plasma cells. Patients 
with a low plasma cell burden may be eligible for 
autologous stem cell transplant if they meet strict 
selection criteria.18 Other patients can be treated 
with a bortezomib based regimen.18 Ideally, such 
patients should be seen at a center of excellence for 
optimal staging and planning of care. It has to be 
emphasized that a patient with MGUS may have 
TTR amyloidosis affecting the heart and this 
possibility increases with older age. Therefore, if 
the amyloidosis syndrome appears to be restricted 
to the heart, a pyrophosphate scan should be 
performed to determine whether the amyloid 
deposits are TTR versus immunoglobulin related. If 
in doubt, then a cardiac biopsy should be performed 
to avoid the possibility of treating a patient with 
TTR amyloidosis using chemotherapy. This 
becomes also more relevant with the availability of 
tafamidis that can treat TTR amyloidosis. 
 
POEMS syndrome 
Patients who present with a progressive 
sensory or sensory-motor polyneuropathy should be 
tested for the presence of a monoclonal protein to 
diagnose or exclude the POEMS syndrome. This is 
an acronym standing for Polyneuropathy, 
Organomegaly, Endocrinopathy, Monoclonal 
protein and Skin changes.19 The neuropathy and 
monoclonal proteins are cardinal features of the 
syndrome. Almost invariably, the M-protein is 
lambda light chain restricted and often is quite 
small in size.20 Immunofixation of the serum is 
essential so as not to miss the small protein that is 
critical for diagnosis. The neuropathy is typical of a 
chronic inflammatory demyelinating type and can 
progress over a matter of weeks. Involvement of the 
respiratory muscles is common and many patients 
may require supplemental oxygen for dyspnea or 
hypoxemia. Pulmonary function studies show a 
‘restrictive pattern’ with low inspiratory and 
expiratory pressures due to respiratory muscle 
weakness. Hepatomegaly, splenomegaly and 
lymphadenopathy are common. The 
endocrinopathies vary and can affect any endocrine 
system of the body with hypogonadism being the 
most common.21 The skin changes are protean and 
include clubbing, leukonychia, hypertrichosis, 
hyper or hypopigmentation and cherry angiomas as 
well as acrocyanosis.22 Other features are captured 
by a second acronym: PEST. Papilledema is 
common in the absence of intracranial pathology. 
Eythrocytosis and Thrombocytosis and also not 
infrequent and sometimes patients are diagnosed 
with a myeloproliferative neoplasm. However, 
careful examination of the bone marrow as well as 
molecular testing will exclude clonal erythrocytosis 
or thrombocytosis.23 Serositis is common leading to 
fluid retention either as lower extremity edema or 
ascites. Pleural effusions are frequent even in the 
absence of heart disease. Vascular endothelial 
growth factor (VEGF) levels are often quite high in 
POEMS syndrome and in the correct clinical 
context are highly suggestive of the diagnosis 
although the test is not specific.24 Proper therapy of 
patients with POEMS syndrome is associated with a 
rapid decline and normalization of VEGF. Patients 
typically have sclerotic bone disease (in contrast to 
the lytic lesions of multiple myeloma) that are best 
detected by PET/CT. Therapy of POEMS syndrome 
depends on whether the cause is an osteosclerotic 
plasmacytoma or diffuse infiltration of the bone 
marrow by clonal plasma cells (often in low 
numbers). For a solitary sclerotic lesion, radiation 
therapy is the standard of care but if there is diffuse 
marrow involvement, chemotherapy or autologous 
stem cell transplantation is the best approach.25 The 
peri-transplant care of these patients can be quite 
challenging due to their multisystem disorder, 
problems with fluid retention and respiratory 
muscle weakness. These patients seem to be a 
significant risk of peri-engraftment syndrome that 
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needs to be promptly diagnosed and treated with 
glucocorticosteroids. 
 
Idiopathic Capillary leak syndrome (Clarkson’s 
disease) 
Patients with Clarkson’s disease present with 
repeated episodes of hypotension followed by fluid 
retention.26 Often the patient is diagnosed with 
dehydration and given large volumes of intravenous 
fluids to raise the blood pressure. However, a 
careful history will fail to find any reasonable 
mechanism for the dehydration. The clue to the 
diagnosis is the presence of hemoconcentration 
(elevated hemoglobin and hematocrit) with 
concomitant low serum protein and albumin 
concentrations: this combination is pathognomonic 
of the phenomenon of capillary leak. The patient 
will have no evidence of chronic liver disease, 
nephrotic syndrome or a protein losing enteropathy 
that would otherwise explain the low serum protein 
and albumin. Nor would there be any evidence for 
an acute infectious or inflammatory insult that could 
lead to extravasation of fluid and protein. Over the 
course of a few days these laboratory anomalies 
will return to normal as the episode of capillary leak 
resolves. The mechanisms that trigger these 
sporadic and potentially life threatening episodes 
are unclear and they can occur anywhere and at any 
time. Patients with this syndrome will have a 
monoclonal protein that in the proper context would 
help establish the diagnosis. Often patients are 
misdiagnosed as septic shock or with angioedema, 
cardiac dysfunction or autonomic failure but a 
complete blood count and serum albumin and 
protein during an acute episode provide the 
evidence for hemoconcentration and in the presence 
of the monoclonal protein (typically an IgG 
kappa)27 establish the diagnosis. Therapy is with 
monthly intravenous immune globulin that is 
generally very effective.28 Other patients may be 
treated with beta agonists as well as theophylline.29 
 
Scleromyxedema 
Scleromyxedema is a multisystem disorder 
due to the deposition of immunoglobulins in 
various organs including the skin (waxy papules or 
plaques) and internal organs such as the 
gastrointestinal tract, the heart and rarely the central 
nervous system. Patients often present with joint 
and skin stiffness, tightening and thickening of the 
skin, dysphagia, or even seizures. When restricted 
to the skin, the condition has a better prognosis. 
Involvement of the heart, lungs or brain is 
associated with a guarded prognosis. It has 
similarities to systemic sclerosis except for the 
waxy papules that may occur on the fingers, behind 
the ears, or over extensor surfaces (e.g. elbow). 
Patients will also have a monoclonal protein in their 
serum but typically there will be very few plasma 
cells in the bone marrow.30 The disease can be 
rapidly progressive and therefore prompt 
recognition is important. Immunomodulatory drugs 
such as lenalidomide are highly effective. Patients 
may also have an excellent and prolonged response 
to autologous stem cell transplantation.31 
Intravenous immune globulin may also be effective, 
although it has to be given long term.32 
 
TEMPI syndrome 
A syndrome characterized by Telangiectasis, 
erythrocytosis with elevated Erythropoietin levels, 
Monoclonal protein, Perinephric fluid collections 
and Intrapulmonary shunting was initially reported 
in 2011 and since then several more cases have 
been described.33-34 The patient may have extreme 
erythrocytosis and with a very high erythropoietin 
level suggesting a reactivbe increase in 
erythrocytes. Patients will have hypoxemia due to 
intrapulmonary shunting which may be quantitated 
using radionuclide approaches. The causative role 
of the plasma cell disorder in this syndrome is 
supported by resolution of symptoms and sign with 
therapy directed at the clonal plasma cells. 
Bortezomib based therapy35 or even autologous 
stem cell transplantation36 may lead to long term 
disease control.  
 
Monoclonal gammopathy of renal significance 
The nephrotoxic potential of monoclonal 
proteins have been known for a long time. The best 
characterized is myeloma cast nephropathy where 
monoclonal immunoglobulin light chains form casts 
that obstruct the renal tubules leading to renal 
failure.37 This is a common presentation of multiple 
myeloma and perhaps 30% of patients will present 
with primarily renal dysfunction as the sole 
manifestation of multiple myeloma. These patients 
typically have very high monoclonal protein levels 
both in the urine and serum. Very high serum 
immunoglobulin free light chains in a patient with 
renal failure are highly suggestive of myeloma cast 
nephropathy and signal the need for urgent therapy 
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to salvage kidney function.38 However, monoclonal 
proteins can cause a wide variety of renal 
pathologies, even when present in low 
concentrations. AL amyloidosis was discussed 
earlier in this review. More recently, the concept of 
monoclonal gammopathy of renal significance 
(MGRS) was proposed and it encompasses a 
spectrum of renal conditions.39 
 
Membranoproliferative glomerulonephritis 
In a recent series of patients with 
membranoproliferative glomerulonephritis (MPGN) 
who did not have any associated infection, 
connective tissue disorder, any evidence of 
complement dysregulation or other malignancies, 
41% were found to have monoclonal deposits 
(usually IgG3) and complement that were identical 
to those in the circulation and/or urine and of the 
same isotype as the clonal plasma cells in the bone 
marrow.40 These deposits appear granular on 
histology and present with the typical hematuria 
proteinuria, hypertension and impaired renal 
function. Often the monoclonal protein is kappa 
light chain restricted. Therapy directed at the 
plasma cells is critical to salvage kidney function. A 
bortezomib based regimen such as 
cyclophosphamide, bortezomib and dexamethasone 
(CyBorD) is generally recommended.41 
 
Immunotactoid glomerulonephritis 
Patients with this condition present with a 
‘nephritic syndrome’ namely, an active urine 
sediment that includes hematuria and proteinuria, 
azotemia and hypertension. Biopsy of the kidney 
shows organized microtubular deposits of 
immunoglobulins, typically IgG in contrast to the 
disorganized monoclonal deposits seen in 
monoclonal immunoglobulin deposition disease.  
 
Acquired Fanconi syndrome 
This syndrome is normally suspected in 
patients with hypophosphatemia with a low 
potassium and low serum uric acid levels in the 
context of significant azotemia. A metabolic 
acidosis without an anion gap is also present. As an 
acquired type of renal tubular acidosis, patients with 
have glycosuria and aminoaciduria. Most often, 
patients have a kappa light chain restricted 
monoclonal protein and they may have 
immunoglobulin crystals in the proximal tubules on 
renal biopsy. Therapy of the underlying plasma cell 
disorder often leads to improvement of the acquired 
Fanconi phenotype.42 
 
Neurologic syndromes 
Sensorimotor peripheral neuropathy 
In patients who present with an acquired, 
distal demyelinating and symmetric neuropathy, 
monoclonal protein should be performed, especially 
if a clear etiology of the neuropathy (e.g. hereditary, 
diabetes mellitus, alcohol and medication effect) 
cannot be established. The strongest association 
between MGUS and neuropathy is for patients with 
a monoclonal IgM. Many of these patients will have 
anti-myelin associated glycoprotein (MAG) 
antibodies, although these are not specific. Non-
IgM related neuropathy often presents as length 
dependent sensory motor neuropathy to classic 
chronic inflammatory demyelinating 
polyneuropathy (CIDP) with predominantly motor 
nerve involvement. Often patients with IgM related 
neuropathy will have features of demyelination on 
EMG while IgG related neuropathy is often 
associated with electro-diagnostic features of 
axonopathy. In all these patients, AL amyloidosis 
and POEMS syndrome need to be excluded. Given 
the relatively high frequency of MGUS in the 
population above the age of 50, it has been difficult 
to prove a causal association between MGUS and 
neuropathy, except perhaps for IgM (43). Therapy 
is often unsatisfactory and includes intravenous 
immunoglobulin, plasmapheresis, rituximab or in 
patients with Waldenstrom’s macroglobulinemia 
bendamustine with rituximab. Given the limited 
data of a link between IgG and CIDP, patients who 
present with the latter should be treated with 
standard therapy such as plasmapheresis, IVIG or 
glucocorticosteroids. 
 
Sporadic late onset nemaline myopathy 
This is a rare acquired myopathy that 
generally presents after the age of 40 years. Patients 
present with a sub-acutely progressive, 
proximal/axial (or less likely distal) muscle 
weakness often associated with dysphagia and 
respiratory muscle weakness. Symptoms may be 
asymmetric in some patients. Muscle enzymes are 
normal but the EMG shows fibrillation and 
myopathic features.44 At least halve of these 
patients will have a monoclonal protein. Muscle 
biopsy establishes the diagnosis by the presence of 
nemaline structures. Various treatment options are 
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available including autologous stem cell 
transplant45 or lenalidomide with dexamethasone 
that may lead to long term disease control.46  
Skin 
Acquired C1 esterase inhibitor deficiency 
Activation of bradykinin release can lead to 
angioedema that is life threatening if it affects the 
tongue or upper airways. This results from the 
activation of the contact phase with kinin 
production in the absence of C1-esterase inhibitor. 
Although the most common cause of C1 esterase 
inhibitor deficiency is genetic, acquired forms of 
the disease exist and in one large series of 92 
patients, a monoclonal protein was identified in 
28.47 Antibodies against C1 esterase inhibitor were 
found in 17 of these patients. Most of the patients 
had MGUS, although several had multiple myeloma 
or AL amyloidosis. 
Cryoglobulinemia 
Cryoglobulins are proteins that precipitate in a 
temperature dependent manner. Their thermal 
stability may be quite variable and as a result they 
may be asymptomatic or associated with severe 
symptoms. Classically, cryoglobulins are divided 
into 3 types: Type 1 with a monoclonal protein (IgG 
or IgM), Type 2 with a monoclonal protein (IgM) 
and polyclonal IgG with a positive rheumatoid 
factor assay and Type 3 with only polyclonal 
immunoglobulins. Type 1 is invariably associated 
with a clonal plasma cell disorder, typically 
multiple myeloma. Patients generally present with 
Raynaud’s phenomenon although they can also 
have vasculitis symptoms such as skin ulcers, 
livedo reticularis, purpura mononeuropathy or 
mononeuritis multiplex as well as renal 
manifestations including azotemia, proteinuria or a 
‘nephritic syndrome’.48 Patients with Type 1 or 
Type 2 cryoglobulinemia will have a detectable 
monoclonal protein. In general for these patients 
therapy directed at the plasma cell or 
lymphoproliferative clone is indicated.48    
Schnitzler syndrome 
Schnitzler syndrome (SchS) is a rare acquired 
inflammatory disorder characterized by recurrent 
episodes of ‘urticaria’ and the presence of a 
monoclonal protein, typically an IgM.49-52 Other 
associated features include fever, an acute phase 
response (usually with florid elevation of the 
sedimentation rate and CRP), anemia, neutrophil 
leukocytosis as well as thrombocytosis. Many 
patients will have bone or joint pain and imaging 
studies, especially PET/CT may be helpful in 
defining the sclerotic bone lesions or the presence 
of the ‘hot knee’ sign that is often present.53 
Diagnosis is based on the ‘Strasbourg criteria’.50-51 
Typically the urticaria will respond to systemic 
glucocorticosteroids but will recur once therapy is 
tapered. Often the skin lesions migrate from one 
location to another over the course of 48 to 72 hours 
and may be itchy. Biopsy of the skin lesions shows 
a predominantly neutrophilic dermal infiltrate 
without evidence of vasculitis. The serum ferritin is 
normal, in contrast to adult onset Still’s disease. 
Complement levels are also normal and help to 
distinguish from hypocomplementemic urticarial 
vasculitis. Diagnosis of the syndrome is important 
since effective therapy in the form on anakinra, an 
interleukin 1 inhibitor, is highly effective. Patients 
will respond rapidly and completely to this therapy, 
although it will have to be given continuously.50-52  
Necrobiotic xanthogranuloma 
Patients with necrobiotic xanthogranuloma 
present with skin plaques that may be pink to red in 
color, or subcutaneous nodules with a predilection 
to occur around the orbit, flexural areas and the 
trunk.54-55 In a significant number of patients, the 
lesions may ulcerate. Histologically, the dermis and 
subcutaneous tissue have a granulomatous infiltrate 
with bands of hyaline necrobiosis as well as Touton 
giant cells. Cholesterol clefts, lymphoid nodules 
with or without germinal centers, and focal 
accumulation of plasma cells may also be present. 
Helper T cells may be found in the granulomas. 
Immunologic studies will confirm that these are 
non-X histiocytosis. Many patients will have an 
associated monoclonal protein (usually Ig) and a 
significant number will have hyperlipidemia and 
low levels of C4. Therapy directed at the plasma 
cell disorder usually results in a complete resolution 
of the necrobiotic xanthogranulomas.56  
Conclusion 
The spectrum of conditions associated with 
monoclonal gammopathy is ever increasing12 and 
recognition of the association between monoclonal 
proteins and other clinical features may assist in 
establishing the diagnosis of life threatening 
conditions. Although many patients with 
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monoclonal gammopathy may turn out to have 
MGUS and that simply need follow up, we cannot 
afford to miss important associated conditions. The 
size of the monoclonal protein has no predictive 
value with respect to the disease associations that 
need to be carefully excluded based on the old 
fashioned history and physical examination and 
targeted testing. 
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